Nasal drug delivery is described as a course of conduct in which drugs are inserted through the nose. The process is direct & quick to administer and can act as a great alternative to other forms of drug delivery routes. The concentration of drug, dose, and volume are important parameters that need to be addressed before administering the nasal drug delivery route. According to research conducted through the market database, the increased volumes or extensive repetitive use can cause damage to the nasal passage.
The nasal cavity is covered with a thin layer of mucosa and a drug molecule can easily breach the layer to enter the blood circulation of a human system. This has opened up great opportunities in the field of research to devise optimum dosages that be can be administered via the nasal passage. Various forms of drugs and vaccines can be formulated to provide easy access to the human system. Research has also been conducted to treat or prevent various neurodegenerative disorders. The increased research infrastructure within this field can be studied through Global Market Database. The cloud-based market research tool studies the shift in line with changing market trends.
Dosage Form and Container Type:
The drugs can be produced in different forms to easily travel through the nasal passage. Sprays, drops & liquids, powders, and gels are the major types of dosage forms available in the market. According to market research tools, nasal sprays have experienced a greater share in the market. This is due to the ease-of-use functionality of the nasal sprays and is also cost-effective. The drivers for this vertical can also be examined using Global Market Database. The market research tool produces free market data across 600+ markets.
Increased cases of common infections and rhinitis have caused the widespread adoption of nasal sprays. The market outlook is expected to stay buoyant for such type. Drops & Liquids are another vertical which have contributed significantly according to market research reports. They are mainly used in hospitals and clinics to drive quick recovery of common infections.
Based on the container type the nasal delivery drugs are bottled in pressurized or non-pressurized containers. Pressurized containers are generally utilized for nasal sprays and non-pressurized containers are used for drops, powders, and gels. The non-pressurized container has significant advantages such as being a quick and effective delivery mechanism.
System Type and Applications:
The nasal drug delivery can be administered in different quantities depending upon the infection. In a multi-dose system, the nasal drug delivery is conducted in regular phases which can span for several weeks or months. The gap between the nasal dosages is advised by the healthcare expert. Bi-dose systems employ only two phases of drug delivery and administer greater concentrations of the drug. Unit-dose systems are expected to grow at a faster rate. This is due to the time factor and ease of administrating in such a system. According to market research tools, this has contributed towards an optimistic market outlook for the unit-dose system.
The nasal drug delivery is utilized for the treatment of allergic and non-allergic rhinitis. The market penetration rate of this technology can be studied using Global Market Database. The market research tool studies the changing market trends through quarterly market data up-dating.
They are also employed for the treatment of reversible airflow obstruction resulted from asthma and chronic obstructive pulmonary disease (COPD). Basic nose congestion treatment makes use of gels or liquids for faster relief. Improved research designs are now focused on nasal vaccine delivery mechanisms.
The COVID-19 has captured the attention of various institutes and companies to develop vaccines that can be administered via the nasal pathway. The market intelligence tool studies the business recovery and the change in market outlook as well. Major market players have started the pre-clinical trials of such types of vaccines to provide ease of use and bring down the costs.
Growth Catalysts:
According to the market database, increased awareness and acceptance by the patients for nasal drug delivery mechanisms has fueled the business recovery in this market. Further benefits which include being non-invasive, easy administration, improved portability, and being cost-effective have contributed significantly towards the growth. The growth dynamics of this sector can also be studied through market research tools. Secondary market research can be performed via platforms like Global Market Database to procure relevant market information.
According to the market database, greater attention is now captured by at-home delivery mechanisms and drugs which follow a unit-dose regime. According to market research led by Binghamton University, State University in New York, in 2018, stated that a single-step nasal spray system is the easiest and most efficient way for nasal delivery.
Increased cases of respiratory diseases which require immediate and quick nasal delivery systems have contributed towards greater adoption. According to market research reports as of 2018, published by the Global Asthma Network, around 330 million people suffered from asthma worldwide. Further growth elements include the benefits of painless drug administration and significant technological advancement to drive innovation.
The global COVID-19 infection has acted as a major catalyst and contributed significantly towards a positive market outlook for the nasal drug delivery market. Ubiquitous testing devices and manual swabs were utilized to test and analyze the COVID-19 samples. This provided for a more quick and painless testing procedure which contributed significantly towards the data for analysis. Major companies have reported projects in the pipeline related to the single-dose system for the COVID-19 vaccine. A vaccine via the nasal pathway can easily enter the blood system and block further entry of the virus. According to market research tools, this is also expected to lead towards reduced costs as it won’t require needles for administration.
The North American Region:
According to the market database, North America has experienced a significant share in the nasal drug delivery market. This is due to the well-established healthcare module and powerful research capacity. A great number of prominent pharmaceutical companies have headquarters present over here. A significant rise in respiratory or nasal type diseases has been witnessed here. The business recovery in this region is expected to be contributed by the healthcare module and transformations in the drug delivery mechanisms.
According to the Center for Disease Control (CDC) in 2017, 30.8 million individuals were diagnosed with sinusitis in the U.S. Also, in the year 2018, 20.4 million adults were having asthma. Market database states that this was approximately 8.3% of the total population in the U.S. 6.1 million children below the age of 18 were diagnosed with asthma in the same year. Quality and safety for nasal drug delivery are overlooked by the Food and Drug Administration (FDA). Stringent policies are drafted to maintain Good Manufacturing Practices (GMP) in this region. The impact of policies on the global markets is expected to shape the upcoming market outlook.
Europe Region Analysis:
This region has maintained the second position in the nasal drug delivery market. Factors that contributed to this demand include the increased awareness by the individuals and healthcare experts to administer the drugs using the nose.
Due to COVID-19 greater research activities are now concentrated towards developing a vaccine that can be inserted into the human body via the nasal pathway. The expansion in market size and the overall market outlook can also be examined using this market research tool. Greater participation by non-profit organizations has been observed here. These organizations have helped to deliver the products or equipment to individuals to grant easy access.
Further research activities are focused on neurodegenerative diseases. Treatment or prevention of such diseases can be aided by the nasal drug delivery market. Major companies have collaborated with different research institutes to find an apt solution. For instance, in 2016, a major company in Norway announced a project to monitor nose-brain applications which are funded by the Research Council of Norway. This is done to treat narcolepsy with the use of bi-directional breath-powered delivery technology.
APAC Region Point of View:
The Asian Pacific region has attracted the attention of major nasal drug delivery market players due to the low-cost manufacturing environment and availability of labor. According to market research tools, China and India are expected to be key contributors to this market. This is due to a greater number of unmet medical needs and increased investment by the government to develop a robust healthcare infrastructure.
In 2018, in a study published in the U.S national library of Medicine National Institute of Health, the prevalence of asthma was found to be the highest in Korea for the APAC region. This has fueled research activities in this vertical to develop innovative nasal drug delivery procedures.
One of the major companies in India has officially entered pre-clinical trials to develop a nasal vaccine for the COVID-19 virus. The human trials are expected to be started in March 2021. This is supposed to be a single-dose vaccine (one in each nostril) to provide immunity against the virus. The vaccine is proposed to target the nasal mucosa to block the infection and transmission.
